NumFin

CytoTools AG

Symbol: T5O.DE

XETRA

0.406

EUR

Market price today

  • -4.2935

    P/E Ratio

  • 0.0000

    PEG Ratio

  • 2.02M

    MRK Cap

  • 0.00%

    DIV Yield

CytoTools AG (T5O-DE) Financial Statements

Download
AnnualQuarterly
LinearLog
On the chart you can see the default numbers in dynamics for CytoTools AG (T5O.DE). Companys revenue shows the average of NaN M which is NaN % gowth. The average gross profit for the whole period is NaN M which is NaN %. The average gross profit ratio is NaN %. The net income growth for the company last year performance is NaN % which equals NaN % % on average for the whole company history.,

AnnualQuarterly
10Y20Y30Y40Y

Balance Sheet

Diving into the fiscal trajectory of CytoTools AG, we observe an average asset growth. This rate, interestingly, stands at , reflecting both the company's highs and lows. When compared quarter-over-quarter, this figure adjusts to . A look back at the past year reveals a total asset change of NaN. Shareholder value, as depicted by the total shareholder equity, is valued at NaN in the reporting currency. The year over year change in this aspect is NaN%.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009

balance-sheet.row.cash-and-short-term-investments

01.801.6
2
2.7
2.1
1.4
3.3
0.7
1.8
1.3
3.2
1.4
1.7

balance-sheet.row.short-term-investments

000-0.2
0
0
0
0
0
0
0
0
0
0
0.4

balance-sheet.row.net-receivables

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.inventory

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-current-assets

00.10.10.1
0
0
0
0
0
0
0
0
0
1.7
0

balance-sheet.row.total-current-assets

020.11.7
2.1
3
2.4
1.5
3.3
0.8
1.9
1.6
3.4
3.4
1.8

balance-sheet.row.property-plant-equipment-net

0000
0
0
0
0.1
0
0
0
0
0
0
0

balance-sheet.row.goodwill

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.intangible-assets

0000.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0
0

balance-sheet.row.goodwill-and-intangible-assets

0000.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0.1
0
0

balance-sheet.row.long-term-investments

019.718.220.5
15.7
13.3
10
8.5
7.5
7.9
8.2
4.6
0
0
1.9

balance-sheet.row.tax-assets

00020.6
15.8
13.4
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-non-current-assets

0-19.7-18.2-20.6
-15.8
-13.4
-10.1
-8.7
-7.6
0
-8.4
-4.8
2.7
2.2
0.4

balance-sheet.row.total-non-current-assets

019.718.220.6
15.8
13.4
10.1
8.7
7.6
8.1
8.4
4.8
2.8
2.2
2.2

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

021.618.322.3
17.9
16.4
12.5
10.1
11
8.8
10.3
6.3
6.3
5.6
4

balance-sheet.row.account-payables

000.10.1
0
0
0
0
0
0
0
0
0.1
0
0

balance-sheet.row.short-term-debt

000.10
0.1
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.tax-payables

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.long-term-debt-total

000.10
0
0
0
0
0
0
0
0
0
0
0

Deferred Revenue Non Current

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.deferred-tax-liabilities-non-current

0---
-
-
-
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

0000
0
0
0
0
0
0
2
0
0
1.4
0.3

balance-sheet.row.total-non-current-liabilities

00.10.20.3
0.1
2.8
1.9
0.1
0
0.2
0.2
0.1
0.1
0
0.1

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-liab

00.20.40.4
0.1
2.9
2
0.1
0.1
0.3
2.2
0.1
0.2
1.5
0.4

balance-sheet.row.preferred-stock

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.common-stock

05.144
3.7
2.7
2.1
2
2
1.9
1.9
1.7
1.7
1.4
1.4

balance-sheet.row.retained-earnings

0-21.4-20.6-16.6
-16.6
-13.4
-12
-10.9
-10
-8.4
-8.8
-7
-7.1
-5.9
-5.1

balance-sheet.row.accumulated-other-comprehensive-income-loss

00.40.434.5
30.8
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.other-total-stockholders-equity

037.3340
-0.2
24.2
20.4
18.9
18.9
15
15
11.5
11.4
8.6
7.3

balance-sheet.row.total-stockholders-equity

021.417.921.9
17.7
13.5
10.5
10
10.9
8.5
8.1
6.2
6.1
4.1
3.6

balance-sheet.row.total-liabilities-and-stockholders-equity

021.618.322.3
17.9
16.4
12.5
10.1
11
8.8
10.3
6.3
6.3
5.6
4

balance-sheet.row.minority-interest

0000
0
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.total-equity

021.417.921.9
17.7
13.5
-
-
-
-
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

0---
-
-
-
-
-
-
-
-
-
-
-

Total Investments

019.718.220.3
15.7
13.3
10
8.5
7.5
7.9
8.2
4.6
2.7
2.2
2.2

balance-sheet.row.total-debt

000.10
0.1
0
0
0
0
0
0
0
0
0
0

balance-sheet.row.net-debt

0-1.80.1-1.6
-2
-2.7
-2.1
-1.4
-3.3
-0.7
-1.8
-1.3
-3.2
-1.4
-1.3

Cash Flow Statement

The financial landscape of CytoTools AG has seen a noteworthy change in free cash flow over the last period, exhibiting a shift of NaN. The company recently extended its share capital by issuing NaN, marking a difference of NaN compared to the previous year. The company's investing activities resulted in net cash usage, amounting to NaN in the reporting currency. This is a shift of NaN from the previous year. In the same period, the company recorded NaN, NaN, and NaN, which are significant to understanding the company's investment and repayment strategies. The company's financing activities led to a net cash usage of NaN, with a year over year difference of NaN. Furthermore, the company allocated NaN for dividend payouts to its shareholders. At the same time, it engaged in other financial maneuvers, referred to as NaN, which also significantly impacted its cash flow during this period. These components, taken together, paint a comprehensive picture of the company's financial status and strategic approach towards cash flow management.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009

cash-flows.row.net-income

0-0.8-4.1-1.8
-1.3
-1.4
-1.1
-1
-1.3
-1
-1.1
-0.7
-0.8
-0.7
-0.7

cash-flows.row.depreciation-and-amortization

002.50
0
0
0
0
0
0
0
0
0
0
0.2

cash-flows.row.deferred-income-tax

0000
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

0000
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0-0.1-0.10.2
0.2
0.1
-0.1
0
-0.2
0.1
0.2
-0.1
0.4
-0.8
0

cash-flows.row.account-receivables

0000
0
0
0
0
0
0.1
0.1
0
0
0
0

cash-flows.row.inventory

0000
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.account-payables

0000
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-0.1-0.10.2
0.2
0
0
0
-0.2
0
0.1
-0.1
0
0
0

cash-flows.row.other-non-cash-items

0000
0.1
0
0
0
0
0
0
0
0
0
-0.4

cash-flows.row.net-cash-provided-by-operating-activities

0000
0
0
0
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

00-0.10
0
0
0
-0.1
0
0
0
0
-0.1
0
0

cash-flows.row.acquisitions-net

0000
0
0
0
0
-0.4
-0.3
0
0
0.1
0
0

cash-flows.row.purchases-of-investments

0-1.50-4.8
-2.4
-3.3
-1.5
-1
-0.1
-2.7
-1.6
-1.3
-0.1
0
-0.5

cash-flows.row.sales-maturities-of-investments

0000
0
0
0
0
0.5
1.1
0
0
0.1
0
0

cash-flows.row.other-investing-activites

0000
0
0
0
0
0.4
0.3
0
0
-0.1
0
0

cash-flows.row.net-cash-used-for-investing-activites

0-1.5-0.1-4.8
-2.4
-3.3
-1.5
-1
0.4
-1.6
-1.6
-1.3
-0.2
0
-0.5

cash-flows.row.debt-repayment

0-0.100
-1.1
-0.5
0
0
0
0
0
0
0
0
0

cash-flows.row.common-stock-issued

04.400
0.1
1.5
1.4
0.1
4.2
2.8
6.3
0.7
4.3
3.4
3.5

cash-flows.row.common-stock-repurchased

0000
-2.3
0
0
0
-0.5
-1.3
-3.3
-0.6
-1.9
-1.8
-1.2

cash-flows.row.dividends-paid

0000
-3.3
0
0
0
0
0
0
0
0
0
0

cash-flows.row.other-financing-activites

0006
9.2
4.2
1.9
0
0
0
0
0
0
0
0

cash-flows.row.net-cash-used-provided-by-financing-activities

04.206
2.7
5.2
3.3
0.1
3.6
1.5
3
0.1
2.4
1.5
2.3

cash-flows.row.effect-of-forex-changes-on-cash

0000
0
0
0
0
0
0
0
3.2
0
0
0

cash-flows.row.net-change-in-cash

01.8-1.7-0.4
-0.7
0.6
0.6
-1.9
2.5
-1.1
0.5
-1.9
1.8
0.1
0.9

cash-flows.row.cash-at-end-of-period

01.8-0.11.6
2
2.7
2.1
1.4
3.3
0.7
1.8
1.3
3.2
1.4
1.3

cash-flows.row.cash-at-beginning-of-period

001.62
2.7
2.1
1.4
3.3
0.7
1.8
1.3
3.2
1.4
1.3
0.4

cash-flows.row.operating-cash-flow

0-0.9-1.6-1.7
-0.9
-1.3
-1.1
-1
-1.5
-0.9
-0.9
-0.7
-0.4
-1.4
-0.9

cash-flows.row.capital-expenditure

00-0.10
0
0
0
-0.1
0
0
0
0
-0.1
0
0

cash-flows.row.free-cash-flow

0-0.9-1.7-1.7
-0.9
-1.3
-1.2
-1
-1.5
-0.9
-0.9
-0.7
-0.6
-1.4
-0.9

Income Statement Row

CytoTools AG's revenue saw a change of NaN% compared with the previous period. The gross profit of T5O.DE is reported to be NaN. The company's operating expenses are NaN, showing a change of NaN% from the last year. The expenses for depreciation and amortization are NaN, which is a NaN% change from the last accounting period. Operating expenses are reported to be NaN, which shows a NaN% year-over-year change. Selling and marketing expenses are NaN, which is a NaN% change compared to the previous year. The EBITDA based on the recent numbers is NaN, representing a NaN% year-over-year growth. The operating income is NaN, which shows a NaN% change when compared to the previous year. The change in the net income is NaN%. The net income for the last year was NaN.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012201120102009

income-statement-row.row.total-revenue

0000
0
0
0.1
0
0
0.3
0.1
0.1
0.1
0.1
0.1

income-statement-row.row.cost-of-revenue

000.50.7
0.3
0.4
0.4
0.3
0.4
0.3
0.5
0.3
0
0.1
0

income-statement-row.row.gross-profit

00-0.5-0.7
-0.3
-0.4
-0.3
-0.3
-0.4
0
-0.5
-0.2
0.1
0
0

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

0000
0
0
0
0
0
0
0
0
0
0
-0.2

income-statement-row.row.operating-expenses

00.81.61.1
0.9
0.8
0.7
0.7
0.9
1
0.7
0.5
0.9
0.6
0.5

income-statement-row.row.cost-and-expenses

00.81.61.9
1.2
1.2
1.1
1
1.3
1.3
1.2
0.7
0.9
0.7
0.5

income-statement-row.row.interest-income

0000
0.1
0.1
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

0000
0.1
0.3
0.1
0
0
0
0
0
0
0
0

income-statement-row.row.selling-and-marketing-expenses

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

00-2.50
-0.1
-0.2
0
0
0
0
0
0
0
0
0

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

0000
0
0
0
0
0
0
0
0
0
0
-0.2

income-statement-row.row.total-operating-expenses

00-2.50
-0.1
-0.2
0
0
0
0
0
0
0
0
0

income-statement-row.row.interest-expense

0000
0.1
0.3
0.1
0
0
0
0
0
0
0
0

income-statement-row.row.depreciation-and-amortization

002.50
0
0
0
0
0
0
0
0
0
0
0.2

income-statement-row.row.ebitda-caps

0---
-
-
-
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

0-0.8-1.6-1.8
-1.2
-1.2
-1
-1
-1.3
-1
-1.1
-0.7
-0.8
-0.7
-0.7

income-statement-row.row.income-before-tax

0-0.8-4-1.8
-1.3
-1.4
-1.1
-1
-1.3
-1
-1.1
-0.7
-0.8
-0.7
-0.7

income-statement-row.row.income-tax-expense

0000
0
0
0
0
0
0
0
0
0
0
0

income-statement-row.row.net-income

0-0.8-4.1-1.8
-1.3
-1.4
-1.1
-1
-1.3
-1
-1.1
-0.7
-0.8
-0.7
-0.7
Similar Stocks
You may also be interested in:
MRVI
Maravai LifeSciences Holdings, Inc..
9.86 USD
NASDAQ
CMRA
Comera Life Sciences Holdings, Inc..
0.02684 USD
NASDAQ
GUBRA.CO
Gubra A/S.
338 DKK
CPH
6826.HK
Shanghai Haohai Biological Technology Co., Ltd..
42 HKD
HKSE
PPBT
Purple Biotech Ltd..
0.67 USD
NASDAQ
SPHRF
Starpharma Holdings Limited.
0.0774 USD
PNK

Frequently Asked Question

What is CytoTools AG (T5O.DE) total assets?

CytoTools AG (T5O.DE) total assets is 21607950.000.

What is enterprise annual revenue?

The annual revenue is N/A.

What is firm profit margin?

Firm profit margin is 1.000.

What is company free cash flow?

The free cash flow is -0.082.

What is enterprise net profit margin?

The net profit margin is -29.508.

What is firm total revenue?

The total revenue is -30.361.

What is CytoTools AG (T5O.DE) net profit (net income)?

The net profit (net income) is -829837.250.

What is firm total debt?

The total debt is 0.000.

What is operating expences number?

The operating expences are 835230.000.

What is company cash figure?

Enretprise cash is 0.000.